Important Information for Investors of ESSA Pharma Inc.: Rosen Law Firm Reminds of the Lead Plaintiff Deadline
New York, NY, Feb. 23, 2025 – Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of the securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. The lawsuit aims to recover damages for ESSA Pharma investors under the Securities Act of 1933.
Background
ESSA Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of rare and chronic orphan diseases. During the Class Period, the Company issued several positive updates regarding its lead product candidate, EPI-5895, a potassium channel activator for the potential treatment of primary hyperkalemia (high potassium levels in the blood).
Allegations
The lawsuit alleges that ESSA Pharma and certain of its top executives made materially false and misleading statements and failed to disclose material information during the Class Period. Specifically, the complaint alleges that the Company downplayed the risks associated with EPI-5895’s clinical trials, overstated the potential market size for the drug, and failed to disclose that the Company was experiencing delays in its regulatory submission timeline.
Impact on Individual Investors
If you purchased ESSA Pharma securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline in this action is March 25, 2025. The lead plaintiff is the investor with the largest financial interest in the relief sought by the class. If you wish to serve as the lead plaintiff, you must apply before this deadline. You may also request information about the claims process by contacting the Rosen Law Firm.
Impact on the World
The allegations against ESSA Pharma could have broader implications for the biopharmaceutical industry. If the allegations are proven, it could lead to increased scrutiny of clinical trial data and regulatory submissions, potentially delaying the approval and commercialization of new drugs. Additionally, it could deter investors from investing in biopharmaceutical companies with uncertain regulatory paths or questionable clinical data.
Conclusion
Investors who purchased ESSA Pharma securities during the Class Period and believe they have suffered a loss as a result of the Company’s alleged misrepresentations have until March 25, 2025, to apply to serve as the lead plaintiff in this class action. If you wish to join the class, or if you have any questions regarding this announcement or your rights, please contact the Rosen Law Firm.
- Rosen Law Firm reminds investors of the lead plaintiff deadline in the ESSA Pharma securities class action.
- The lawsuit alleges that ESSA Pharma and its executives made materially false and misleading statements during the Class Period.
- The impact of the allegations could extend beyond ESSA Pharma, potentially affecting the biopharmaceutical industry as a whole.
- Individual investors who purchased ESSA Pharma securities during the Class Period and believe they have suffered a loss may be entitled to compensation.
